Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Chinese startups can develop digital avatars almost as good as human streamers using just a few minutes of footage, noted ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, will be hosting Pharma.AI Week featuring in-depth webinar series from November ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

SAN FRANCISCO — While generative AI (AI) is being hailed as a game-changer as it sweeps the globe, the concept of “in silico medicine,” or computational medicine, is not exactly a new one.

With its unique target discovery platforms, PandaOmics and Chemistry42, AI company Insilico is transforming the world of research and development. Deep learning in biopharma has come of age.

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...